Fennec Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors Read more about Fennec Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors
Fennec Pharmaceuticals Expects to Receive Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors Read more about Fennec Pharmaceuticals Expects to Receive Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors
Fennec Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Business Update Read more about Fennec Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Business Update
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences Read more about Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
Fennec Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Business Update Read more about Fennec Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Business Update
FENNEC ANNOUNCES RESULTS OF ANNUAL MEETING Read more about FENNEC ANNOUNCES RESULTS OF ANNUAL MEETING
Fennec Pharmaceuticals Announces Amendment to Increase Existing Senior Debt Facility Read more about Fennec Pharmaceuticals Announces Amendment to Increase Existing Senior Debt Facility
FENNEC PHARMACEUTICALS ANNOUNCES AMENDMENT TO INCREASE EXISTING SENIOR DEBT FACILITY Read more about FENNEC PHARMACEUTICALS ANNOUNCES AMENDMENT TO INCREASE EXISTING SENIOR DEBT FACILITY
FENNEC PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION RESUBMISSION FOR PEDMARK™ Read more about FENNEC PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION RESUBMISSION FOR PEDMARK™
